deltatrials
Completed PHASE2 NCT00520598

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women

Sponsor: Merck Sharp & Dohme LLC

Conditions Cervical Cancer Genital Warts Human Papillomavirus Infection Vaginal Cancer Vulvar Cancer
Interventions Comparator: Placebo (unspecified) Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Comparator: V505 formulation 1 Comparator: V505 formulation 2 Comparator: V505 formulation 3
Updated 7 times since 2017 Last updated: Nov 25, 2015 Started: Oct 31, 2007 Primary completion: May 31, 2011 Completion: May 31, 2011

Listed as NCT00520598, this PHASE2 trial focuses on Cervical Cancer and Genital Warts and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.